Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326)

M. Herman Chui, Susanne K. Kjaer, Kirsten Frederiksen, Charlotte G. Hannibal, Tian Li Wang, Russell S Vang, Ie Ming Shih

Research output: Contribution to journalComment/debatepeer-review

Abstract

This article has been corrected: In Table 2, the numbers in column 2, rows 2 and 3, were accidentally switched. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original languageEnglish (US)
Pages (from-to)1323-1324
Number of pages2
JournalOncotarget
Volume12
Issue number13
DOIs
StatePublished - Jun 22 2021

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Errayum: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma (Oncotarget. (2019) 10 (6870–6878) DOI: 10.18632/oncotarget.27326)'. Together they form a unique fingerprint.

Cite this